Please login to the form below

Not currently logged in


This page shows the latest ISIS-APOCIII Rx news and features for those working in and with pharma, biotech and healthcare.

Biogen Idec gets exclusive access to Isis' neurology R&D

Biogen Idec gets exclusive access to Isis' neurology R&D

In early 2012, Biogen Idec tapped into Isis' antisense technology to try to develop a new drug called ISIS-SMN Rx to treat spinal muscular atrophy. ... Meanwhile, Isis has also just reported encouraging data from a phase II trial ISIS-APOCIII Rx for

Latest news

  • Isis rises on positive triglyceride drug data Isis rises on positive triglyceride drug data

    ISIS-APOCIII Rx can cause triglycerides to drop 75 per cent. Antisense specialist Isis Pharmaceuticals shares leapt this week after the company reported positive data with its triglyceride-lowering drug candidate. ... ISIS-APOCIII Rx achieved a

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...